502 Deputy Billy Kelleher asked the Minister for Health the reason the Health Service Executive continue to deny access to the drug Pradaxa to GMS and DPS patients when its availability is likely to not only save many families from the devastation of a stroke but it will also deliver recoverable long term savings to the State by reducing the number of stroke survivors requiring long term nursing home care at a cost of approximately €50,000 per patient per year; and if he will make a statement on the matter. [24117/12]

Summary

502 Deputy Billy Kelleher asked the Minister for Health the reason the Health Service Executive continue to deny access to the drug Pradaxa to GMS and DPS patients when its availability is likely to not only save many families from the devastation of a stroke but it will also deliver recoverable long term savings to the State by reducing the number of stroke survivors requiring long term nursing home care at a cost of approximately €50,000 per patient per year; and if he will make a statement on the matter. [24117/12]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 15 May 2012

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.